In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Goserelin | Synthetic analog Leuprolide | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Synthetic analog | |
| Area | Sexual health and hormones | Sexual health and hormones | |
| Evidence | |||
| Amount of evidence | 583 | 707 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 122 (119 in people) | 167 (167 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 309 · 71 active108 more mention it but do not test it | 393 · 85 active117 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
The FDA label for Zoladex says: “Zoladex 3.6 mg implant: locally confined Stage T2b-T4 prostate carcinoma with flutamide and radiotherapy; palliation of advanced prostate carcinoma; endometriosis; endometrial thinning before ablation for dysfunctional uterine bleeding; palliation of advanced breast cancer in pre- and perimenopausal women”
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Goserelin | Leuprolide |
|---|---|---|
| Sex hormones and fertilityReproductive and sexual health | 14810741 | 19616630 |
| Adverse events |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The FDA label for Leuprolide acetate for depot suspension says: “Selected three-month depot formulation for advanced prostate cancer”
62593 |
112112 |
| Tumor growthReproductive and sexual health | 938472 | 70682 |
|---|
| Bone and jointMusculoskeletal | 3434 | 2525 |
|---|
| MortalityCardiovascular | 3838 | 1313 |
|---|
| PainWhole body | 1616 | 3535 |
|---|
| Surgical outcomesReproductive and sexual health | 2929 | 1010 |
|---|
| Anxiety and moodMental health and mood | 1111 | 1010 |
|---|
| LipidsMetabolic and weight | 99 | 1010 |
|---|
| Receptor activity and mechanismPharmacology | 151014 | 1459 |
|---|
| Uterine VolumeReproductive and sexual health | 22 | 1616 |
|---|
| Sexual functionReproductive and sexual health | 33 | 14122 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Goserelin differs from Gonadorelin at 3 positions.
What is different
Leuprolide differs from Gonadorelin at 2 positions.
What is different
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 309 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Novartis Pharmaceuticals3,246 participants30 Nov 2016 to 9 Nov 2022
Breast Cancer
SWOG Cancer Research Network3,040 participantsMay 1995 to Jun 2013
Prostate Cancer
Radiation Therapy Oncology Group2,028 participantsOct 1994 to 14 May 2018
Prostate Cancer
108 more mention it but do not test it. They only measure it or name it in their text.
Top 3 of 393 trials, ranked by phase, then posted results and enrollment: 1 ongoing · 2 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Novartis Pharmaceuticals3,246 participants30 Nov 2016 to 9 Nov 2022
Breast Cancer
Radiation Therapy Oncology Group2,028 participantsOct 1994 to 14 May 2018
Prostate Cancer
SWOG Cancer Research Network1,939 participants12 Sept 2013 to est. Jan 2030
Breast Cancer
117 more mention it but do not test it. They only measure it or name it in their text.
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
| Outcome | Goserelin | Leuprolide |
|---|---|---|
| MortalityCancerCompared as: value in the arm that got the peptide, in % | 99.4% Overall survival · goserelin plus tamoxifen at 5 years Dose studied: monthly administration2 yearsn = 1,2822020 | 90.5% Survival rate Dose studied: 7.5 mg every 28 days9 months (253 days)n = 2842003 |
| Tumor growthCancerCompared as: value in the arm that got the peptide, in % | 64% Progression-free survival Dose studied: 10·8 mg on the first day of irradiation and 3 months latern = 7432019 | 86% No progression |
| Sex hormones and fertilityReproductive and sexual healthCompared as: value in the arm that got the peptide, in % | 21% Pregnancy n = 2182015 | 58.5% Pregnancy rate n = 1292005 |
| PainWhole bodyCompared as: value in the arm that got the peptide, in % | 13.1% Symptom recurrence · goserelin at 1 year six monthsn = 2101999 | 23% |
| Surgical outcomesReproductive and sexual healthCompared as: value in the arm that got the peptide, in ml | −187 ml Blood loss · Shown as a change. The study reports a blood loss of this size. Placebo median: −308 ml 3 monthsn = 711994 | |
| Bone and jointMusculoskeletalCompared as: value in the arm that got the peptide, in % | −5.4% Bone mineral density change Dose studied: 3.6 mg every 28 days24 weeksn = 3151993 | −2.5% Bone mineral density change · leuprolide, baseline to 12 months |
| Adverse eventsWhole bodyCompared as: value in the arm that got the peptide, in % | 75% Hot flashes Dose studied: 3.6 mg every 4 weeksn = 1361998 | 40% Moderate-to-severe hot flashes |
99.4%
Overall survival · goserelin plus tamoxifen at 5 years
Dose studied: monthly administration2 yearsn = 1,2822020
90.5%
Survival rate
Dose studied: 7.5 mg every 28 days9 months (253 days)n = 2842003
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Goserelin | Leuprolide |
|---|---|---|
| Organ injuryReproductive and sexual healthCompared as: value in the arm that got the peptide, in % | −53% AFS score reduction · Shown as a change. The study reports a afs score reduction of this size. · goserelin at 24 weeks Dose studied: 3.6 mg every 28 days24 weeksn = 3151993 |
Dose studied: 1 mg/dayn = 1991986
Pain recurrence rate
Dose studied: 3.75 mg monthly3 monthsn = 892001
−280 mL Median blood loss · Shown as a change. The study reports a median blood loss of this size. single injection; 12-week pretreatment periodn = 552020 |
12 monthsn = 522004
Dose studied: 3.75 mg once monthly3 monthsn not reported2012
64%
Progression-free survival
Dose studied: 10·8 mg on the first day of irradiation and 3 months latern = 7432019
86%
No progression
Dose studied: 1 mg/dayn = 1991986
21%
Pregnancy
n = 2182015
58.5%
Pregnancy rate
n = 1292005
13.1%
Symptom recurrence · goserelin at 1 year
six monthsn = 2101999
23%
Pain recurrence rate
Dose studied: 3.75 mg monthly3 monthsn = 892001
−187 ml
Blood loss · Shown as a change. The study reports a blood loss of this size.
Placebo median: −308 ml
3 monthsn = 711994
−280 mL
Median blood loss · Shown as a change. The study reports a median blood loss of this size.
single injection; 12-week pretreatment periodn = 552020
−5.4%
Bone mineral density change
Dose studied: 3.6 mg every 28 days24 weeksn = 3151993
−2.5%
Bone mineral density change · leuprolide, baseline to 12 months
12 monthsn = 522004
75%
Hot flashes
Dose studied: 3.6 mg every 4 weeksn = 1361998
40%
Moderate-to-severe hot flashes
Dose studied: 3.75 mg once monthly3 monthsn not reported2012
No comparable result 1 randomized-trial result measure it in another way or another unit. |
| Menstrual BleedingReproductive and sexual healthCompared as: value in the arm that got the peptide, in % | No comparable result 6 randomized-trial results measure it in another way or another unit. | 83.1% PBAC <10 at weeks 6-12 Dose studied: 1.88 mg or 3.75 mg monthly24 weeksn = 2812019 |
|---|
| Body compositionMusculoskeletalCompared as: value in the arm that got the peptide, in kg | 0.37 kg Leg lean mass change Placebo group: 0.57 kg Dose studied: 3.6 mg every 4 wk12 wkn = 222006 | No comparable result 1 randomized-trial result measure it in another way or another unit. |
|---|
| Exercise and physical functionMusculoskeletalCompared as: value in the arm that got the peptide, in % | No comparable result 3 randomized-trial results measure it in another way or another unit. | −5.1% Change Placebo: 0.2% Dose studied: 11.25 mg every 12 weeks48 weeksn not reported2010 |
|---|
| Cognition and memoryNervous system and cognitionCompared as: value in the arm that got the peptide, in points | No randomized trial result 12 results from other study designs. | 0.18 points ADAS-Cog mean decline · high-dose leuprolide (22.5 mg), AChEI subgroup Placebo, AChEI subgroup: 3.3 points Dose studied: 22.5 mg48 weeksn not reported2015 |
|---|
−53%
AFS score reduction · Shown as a change. The study reports a afs score reduction of this size. · goserelin at 24 weeks
Dose studied: 3.6 mg every 28 days24 weeksn = 3151993
No comparable result
1 randomized-trial result measure it in another way or another unit.
No comparable result
6 randomized-trial results measure it in another way or another unit.
83.1%
PBAC <10 at weeks 6-12
Dose studied: 1.88 mg or 3.75 mg monthly24 weeksn = 2812019
0.37 kg
Leg lean mass change
Placebo group: 0.57 kg
Dose studied: 3.6 mg every 4 wk12 wkn = 222006
No comparable result
1 randomized-trial result measure it in another way or another unit.
No comparable result
3 randomized-trial results measure it in another way or another unit.
−5.1%
Change
Placebo: 0.2%
Dose studied: 11.25 mg every 12 weeks48 weeksn not reported2010
No randomized trial result
12 results from other study designs.
0.18 points
ADAS-Cog mean decline · high-dose leuprolide (22.5 mg), AChEI subgroup
Placebo, AChEI subgroup: 3.3 points
Dose studied: 22.5 mg48 weeksn not reported2015